1. Ketorolac and (-)-Epicatechin change retinal GFAP and NRF2 expression on hyperglycemic CD1 mice.
- Author
-
Somilleda-Ventura SA, López-Mayorga RM, Meaney-Mendiolea E, Rubio-Gayosso AIO, Pérez-Cano HJ, Ceballos-Reyes GM, and Lima-Gómez V
- Subjects
- Animals, Mice, Ketorolac therapeutic use, Ketorolac metabolism, Ketorolac pharmacology, Mice, Inbred C57BL, NF-E2-Related Factor 2 metabolism, NF-E2-Related Factor 2 pharmacology, Retina metabolism, Catechin pharmacology, Catechin therapeutic use, Catechin metabolism, Hyperglycemia drug therapy, Hyperglycemia metabolism, Retinal Diseases
- Abstract
Our objective was to determine whether (-)-Epicatechin administered alone or simultaneously with topical Ketorolac decreased the relative expression of GFAP and modulated the response of Nrf2 in a mouse model with induced hyperglycemia. We found that GFAP and Nrf2 decreased in the groups that received treatments alone or simultaneous during 8 weeks; even when the effect on the Nrf2 was not pronounced, it showed a higher concentration when GFAP decreased. Our results suggest a protective effect of Ketorolac and (-) - Epicatechin, which seem to limit the preclinical retinal damage caused by inflammation in hyperglycemia., Competing Interests: Declaration of Competing Interest None., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF